Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Sodium-glucose cotransporter-2 inhibitors induce less weight loss than expected.

The researchers investigated the separate and combined effects of dapagliflozin and exenatide on the brain in response to the anticipation and consumption of food in people with obesity and type 2 diabetes.

Who Took Part

Using functional magnetic resonance imaging, the effects of treatments on brain responses to the anticipation of food and food receipt were assessed after 10 days and 16 weeks.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

As a double-blind Exenatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

The methods mention a period of 10 days.

As part of a larger study, this was a 16 week, double-blind, randomized, placebo-controlled trial.

What Was Measured

PubMed files the paper under topics including Benzhydryl Compounds, Blood Glucose, Brain, Diabetes Mellitus, Type 2, Exenatide, Glucose and Glucosides.

The authors tagged it with the keywords GLP-1 receptor agonist, SGLT2 inhibitor, central regulation of appetite, dapagliflozin, functional neuroimaging and obesity.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide over 10 days.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page, all human trials.